Amendments to the Specification:

Please replace the second full paragraph on page 15 with the following amended paragraph:

--The mapping of the epitope to which the antibody according to the invention binds showed that this binds to a peptide sequence which occurs twice in the extracellular domain of CD30. The antibody secreted by the cell line DSZ1 according to the invention showed two strong signals with peptides derived from CD30 (*cf.* Figure 3): Spot 16 (with the sequence ^{64}DCRKQCEPDYYLD^{76} (SEQ ID NO:11)) and Spot 74 (^{238}GDCRKQCEPDYYL^{250} (SEQ ID NO:12)). An extensive mapping of the epitope using substitution analysis gave the amino acid residue CEPDY (SEQ ID NO:13) as the core sequence for the interaction. Both epitopes bind the antibody secreted by the cell line according to the invention and the binding was not lost if only one of the epitopes was mutated, whilst mutation in both epitopes led to the loss of the antibody recognition.--

Please replace the second full paragraph on page 7 with the following amended paragraph:

-- In a further preferred embodiment, the reagent reacts with a protein containing the amino acid sequence CEPDY (SEQ ID NO:13) as the core sequence of the epitope. The epitope in question occurs, amongst other things, twice in the CD30 antigen. The identification of an epitope that is recognised by the reagent according to the invention is easily possible using methods commonly used by experts, as is explained in more detail in the examples for the CEPDY (SEQ ID NO:13) epitope.--

Please replace the paragraph on page 12, immediately under the title EXAMPLE 1: PRODUCTION OF THE ANTIBODY ACCORDING TO THE INVENTION, with the following amended paragraph:

--A chimerized CD30 antibody, as produced by the stored cell line DSZ1, is based on the constant regions of the human IgG1κ chain and the variable regions which code the

antigen binding site for the CEPDY (SEQ ID NO:13) epitope of CD30. The latter V genes can be isolated with the following primers:--